Cinclus Pharma
The answer first
Does Cinclus Pharma beat the market?
No, Cinclus Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 9% of Nordic stocks
- Quality50
- Value1
- Trend27
No. 168 of 195 in healthcare
Max for seven days
Follow Cinclus Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Cinclus Pharma
Your first answer is free, no account needed.
Do you own Cinclus Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Cinclus Pharma and a few more. Free, no card.
Super Stock+45.9%In short
- Cinclus Pharma has fallen 34.2% over the past year, including dividends.
- Overall, Cinclus Pharma ranks better than 9% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 73.1%. The price is 67.1% below its peak now.
What do analysts think of Cinclus Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 9% of Nordic stocks.
No. 168 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 131 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.09
- Asset turnoverSales divided by everything the company owns0.09
- Return on equityProfit divided by equity−132.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 192 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity7.9
- P/SPrice divided by sales19.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 111 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−12.1%
- 6 months−5.1%
- 9 months−34.2%
- 12 months−34.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Cinclus Pharma
3 funds we follow own Cinclus Pharma. The share is how much of the fund the stock makes up.
- Sweden3
From the funds' latest known holdings.
About Cinclus Pharma
Cinclus Pharma is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 21 employees.
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.


See the full analysis of Cinclus Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card